Canaccord initiated coverage of Viking Therapeutics (VKTX) with a Buy rating and $106 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics’ VK2735: A Promising Phase 3 Study for Weight Management
- Viking Therapeutics’ VK2735 Study: A Potential Game-Changer for Weight Management in Type 2 Diabetes
- Viking Therapeutics price target lowered to $75 from $80 at JPMorgan
- Viking Therapeutics Navigates Regulatory Risks Amid U.S. Policy Shifts
- Viking Therapeutics’ Earnings Call: Clinical Success Amid Financial Challenges